Aurora Cannabis Inc. (ACB)
USD 4.84
(1.89%)
USD 4.84
(1.89%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -69.32 Million CAD | 73.87% |
| 2022 | -265.32 Million CAD | 84.55% |
| 2021 | -1.71 Billion CAD | -147.63% |
| 2020 | -693.62 Million CAD | 79.05% |
| 2019 | -3.31 Billion CAD | -1038.21% |
| 2018 | -290.83 Million CAD | -504.3% |
| 2017 | 71.93 Million CAD | 654.72% |
| 2016 | -12.96 Million CAD | -126.57% |
| 2015 | -5.72 Million CAD | 39.87% |
| 2014 | -9.51 Million CAD | -2281.35% |
| 2013 | -399.7 Thousand CAD | -1.58% |
| 2012 | -393.48 Thousand CAD | -24.62% |
| 2011 | -315.76 Thousand CAD | 2.09% |
| 2010 | -322.49 Thousand CAD | -634.52% |
| 2009 | -43.9 Thousand CAD | 69.86% |
| 2008 | -145.65 Thousand CAD | 17.84% |
| 2007 | -177.28 Thousand CAD | -14092.58% |
| 2006 | 1267.00 CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -2.12 Million CAD | 99.66% |
| 2023 Q2 | -24.49 Million CAD | -1051.81% |
| 2023 Q3 | -17.4 Million CAD | 28.95% |
| 2023 FY | -69.32 Million CAD | 73.87% |
| 2022 Q3 | 470.45 Million CAD | 819.44% |
| 2022 Q4 | -618.77 Million CAD | -231.53% |
| 2022 Q2 | -65.39 Million CAD | -26.72% |
| 2022 Q1 | -51.6 Million CAD | 91.66% |
| 2022 FY | -265.32 Million CAD | 84.55% |
| 2021 Q4 | -618.42 Million CAD | 38.9% |
| 2021 Q1 | -11.88 Million CAD | 90.72% |
| 2021 FY | -1.71 Billion CAD | -147.63% |
| 2021 Q2 | -75.14 Million CAD | -532.3% |
| 2021 Q3 | -1.01 Billion CAD | -1247.0% |
| 2020 Q4 | -128.12 Million CAD | 22.18% |
| 2020 Q1 | -108.06 Million CAD | 94.31% |
| 2020 Q2 | -292.78 Million CAD | -170.94% |
| 2020 FY | -693.62 Million CAD | 79.05% |
| 2020 Q3 | -164.65 Million CAD | 43.76% |
| 2019 Q3 | -137.39 Million CAD | 89.32% |
| 2019 Q4 | -1.89 Billion CAD | -1282.56% |
| 2019 Q2 | -1.28 Billion CAD | -10182.54% |
| 2019 Q1 | 12.75 Million CAD | 6709.33% |
| 2019 FY | -3.31 Billion CAD | -1038.21% |
| 2018 Q4 | -193 Thousand CAD | 99.88% |
| 2018 FY | -290.83 Million CAD | -504.3% |
| 2018 Q1 | 105.46 Million CAD | 32.04% |
| 2018 Q2 | -237.75 Million CAD | -325.44% |
| 2018 Q3 | -158.35 Million CAD | 33.4% |
| 2017 Q1 | 3.56 Million CAD | 173.92% |
| 2017 Q4 | 79.86 Million CAD | 515.66% |
| 2017 FY | 71.93 Million CAD | 654.72% |
| 2017 Q3 | -19.21 Million CAD | -348.87% |
| 2017 Q2 | 7.72 Million CAD | 116.88% |
| 2016 Q3 | 138.83 Thousand CAD | 105.18% |
| 2016 Q2 | -2.67 Million CAD | 52.29% |
| 2016 FY | -12.96 Million CAD | -126.57% |
| 2016 Q4 | -4.81 Million CAD | -3569.05% |
| 2016 Q1 | -5.61 Million CAD | 24.9% |
| 2015 FY | -5.72 Million CAD | 39.87% |
| 2015 Q4 | -7.47 Million CAD | -395.79% |
| 2015 Q3 | 2.52 Million CAD | 326.16% |
| 2015 Q2 | 592.92 Thousand CAD | 143.31% |
| 2015 Q1 | -1.36 Million CAD | -104.68% |
| 2014 Q2 | -6.25 Million CAD | -1130.12% |
| 2014 Q1 | -508.29 Thousand CAD | -113.66% |
| 2014 Q4 | 29.24 Million CAD | 3882.85% |
| 2014 FY | -9.51 Million CAD | -2281.35% |
| 2014 Q3 | -773.17 Thousand CAD | 87.63% |
| 2013 FY | -399.7 Thousand CAD | -1.58% |
| 2013 Q4 | -237.89 Thousand CAD | -155.91% |
| 2013 Q3 | -92.96 Thousand CAD | -219.46% |
| 2013 Q1 | -39.74 Thousand CAD | 62.3% |
| 2013 Q2 | -29.1 Thousand CAD | 26.78% |
| 2012 Q3 | -73.05 Thousand CAD | -7.27% |
| 2012 FY | -393.48 Thousand CAD | -24.62% |
| 2012 Q1 | -148.91 Thousand CAD | 24.85% |
| 2012 Q2 | -68.1 Thousand CAD | 54.27% |
| 2012 Q4 | -105.41 Thousand CAD | -44.3% |
| 2011 FY | -315.76 Thousand CAD | 2.09% |
| 2011 Q3 | -41.63 Thousand CAD | -18.54% |
| 2011 Q1 | -40.83 Thousand CAD | 25.43% |
| 2011 Q2 | -35.12 Thousand CAD | 13.97% |
| 2011 Q4 | -198.16 Thousand CAD | -375.91% |
| 2010 Q1 | -34.29 Thousand CAD | 28.27% |
| 2010 FY | -322.49 Thousand CAD | -634.52% |
| 2010 Q4 | -54.75 Thousand CAD | 75.21% |
| 2010 Q3 | -220.83 Thousand CAD | -1650.28% |
| 2010 Q2 | -12.61 Thousand CAD | 63.21% |
| 2009 Q2 | -10.19 Thousand CAD | 43.12% |
| 2009 Q1 | -17.92 Thousand CAD | -1.86% |
| 2009 Q3 | -26.47 Thousand CAD | -159.69% |
| 2009 Q4 | -47.8 Thousand CAD | -80.56% |
| 2009 FY | -43.9 Thousand CAD | 69.86% |
| 2008 Q1 | -76.09 Thousand CAD | -238.8% |
| 2008 Q2 | -22.31 Thousand CAD | 70.67% |
| 2008 Q4 | -17.59 Thousand CAD | 40.65% |
| 2008 FY | -145.65 Thousand CAD | 17.84% |
| 2008 Q3 | -29.64 Thousand CAD | -32.84% |
| 2007 Q3 | -4675.00 CAD | 96.89% |
| 2007 Q4 | -22.46 Thousand CAD | -380.43% |
| 2007 Q2 | -150.35 Thousand CAD | -73803.43% |
| 2007 Q1 | 204.00 CAD | 0.0% |
| 2007 FY | -177.28 Thousand CAD | -14092.58% |
| 2006 FY | 1267.00 CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -209.24 Million USD | 66.869% |
| Theratechnologies Inc. | -23.95 Million USD | -189.377% |
| Safety Shot Inc | -15.08 Million USD | -359.629% |
| Cosmos Health Inc. | -18.54 Million USD | -273.873% |
| Cronos Group Inc. | -73.96 Million USD | 6.269% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 93.083% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -64.284% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 1501.941% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -1024.863% |
| ProPhase Labs, Inc. | -16.78 Million USD | -313.097% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -1333.837% |
| Dynavax Technologies Corporation | -6.38 Million USD | -985.084% |
| Radius Health, Inc. | -25.79 Million USD | -168.799% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -2137.382% |
| Alvotech | -551.73 Million USD | 87.435% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -1438.511% |
| Alpha Teknova, Inc. | -36.78 Million USD | -88.488% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 50.366% |
| SCYNEXIS, Inc. | 67.04 Million USD | 203.408% |
| Harrow Health, Inc. | -24.41 Million USD | -183.995% |
| Biofrontera Inc. | -20.13 Million USD | -244.374% |
| DURECT Corporation | -27.62 Million USD | -150.963% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 5367.933% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 469.168% |
| OptiNose, Inc. | -35.48 Million USD | -95.378% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 389.873% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -780.889% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -1004.037% |
| SIGA Technologies, Inc. | 68.06 Million USD | 201.847% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 677.091% |
| Shineco, Inc. | -22.44 Million USD | -208.815% |
| Phibro Animal Health Corporation | 2.41 Million USD | 2969.454% |
| Procaps Group S.A. | 42.54 Million USD | 262.967% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -574.509% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -1511.544% |
| Viatris Inc. | 54.7 Million USD | 226.739% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -1438.511% |
| Rockwell Medical, Inc. | -8.43 Million USD | -721.495% |
| Incannex Healthcare Limited | -18.45 Million USD | -275.567% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -337.554% |
| Tilray Brands, Inc. | -244.98 Million USD | 71.701% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 243.964% |
| PetIQ, Inc. | 2.13 Million USD | 3353.214% |
| Silver Spike Investment Corp. | 7.34 Million USD | 1044.482% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 127.764% |
| Journey Medical Corporation | -3.85 Million USD | -1699.273% |
| Alimera Sciences, Inc. | -20.13 Million USD | -244.357% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -749.252% |
| Assertio Holdings, Inc. | -331.94 Million USD | 79.115% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -951.553% |
| Embecta Corp. | 70.4 Million USD | 198.474% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -245.64% |
| Procaps Group, S.A. | 42.54 Million USD | 262.967% |
| PainReform Ltd. | -9.34 Million USD | -641.931% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 56.746% |
| Hempacco Co., Inc. | -13.12 Million USD | -428.155% |
| Talphera, Inc. | -18.39 Million USD | -276.833% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 265.239% |
| Alvotech | -551.73 Million USD | 87.435% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 121.223% |
| Kamada Ltd. | 8.28 Million USD | 936.866% |
| Indivior PLC | 2 Million USD | 3566.3% |
| Currenc Group, Inc. | -15.3 Million USD | -352.917% |
| Evoke Pharma, Inc. | -7.79 Million USD | -789.674% |
| Flora Growth Corp. | -57.03 Million USD | -21.548% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -245.64% |
| Evolus, Inc. | -61.68 Million USD | -12.387% |
| HUTCHMED (China) Limited | 100.78 Million USD | 168.789% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 150.402% |
| Akanda Corp. | -32.27 Million USD | -114.797% |